Clinical trial
A Phase I/II Study to Determine Feasibility and Safety MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
NCT02535247 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study to Determine Feasibility and Safety MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
- Lead sponsor
- Fox Chase Cancer Center
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- January 5, 2016
- Completion date
- February 25, 2020
- Enrollment
- 17 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.